Dianthus Therapeutics Inc (DNTH) Dividendos

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. The company is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).